Tejaswini Kulkarni, MD, MPH

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Boehringer Ingelheim
    Date added:
    01/14/2025
    Date updated:
    01/14/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Puretech
    Date added:
    01/14/2025
    Date updated:
    01/14/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    United Therapeutics
    Date added:
    01/14/2025
    Date updated:
    01/14/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Aileron
    Date added:
    01/14/2025
    Date updated:
    01/14/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Avalyn
    Date added:
    01/14/2025
    Date updated:
    01/14/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Tempus
    Date added:
    01/14/2025
    Date updated:
    01/14/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Vicore
    Date added:
    01/14/2025
    Date updated:
    01/14/2025
Return to March 14, 2025 31st Advances in Pulmonary and Critical Care Medicine Conference